The Secretary-General of Epidemiological Affairs at the Ministry of Health, Adel Al-Belbisi, confirmed Tuesday during his participation in Roya's Nabd Al-Balad, that there is a noticeable demand by citizens for vaccines, especially the Pfizer-BioNTech jab.

He noted that the Sinopharm vaccine is less popular because some countries have yet to approve it, including Saudi Arabia.

This matter leads to a problem and affects the strategy of the Ministry of Health in vaccine administration, said Belbisi, pointing out that the Ministry of Foreign Affairs addressed the relevant authorities inSaudi Arabia and the World Health Organization (WHO) with the need to intervene and solve the problem, because of its sizeable and harmful impact and considering it harmful. 

He pointed out that this problem will be solved in Saudi Arabia within a week.

Belbisi stressed that mixing between vaccines is out of the question in Jordan (taking two different doses of different vaccines), noting that two different vaccine doses are only administered in rare cases when a person develops hypersensitivity to the initial vaccine taken, and is changed to another vaccine.

He indicated that 1.6 million jabs will be arriving in the Kingdom in June, including 800,000 doses of the Sinopharm vaccine.

Jordan has agreements to obtain a total of 11.5 million vaccine doses, said Belbisi.

He said there are currently over 2,536,000 people are registered on the national platform for COVID-19 vaccination in Jordan.